Proscia

Proscia develops digital pathology software and AI tools for clinical laboratories and life sciences organizations, supporting work from biomedical discovery through diagnosis. Its Concentriq portfolio is designed for biomarker research, clinical trials, companion diagnostics, and pathology case review. The platform helps pathology teams manage and review digital images, while enabling researchers and biopharma companies to investigate tissue, generate biomarker insights, and support therapy development.

Proscia reports that its customers serve more than 4,000 hospitals and clinics worldwide, and that 16 of the top 20 pharmaceutical companies use Concentriq. The company also offers services and resources such as product demonstrations, educational content, and guidance for organizations adopting digital pathology. Concentriq AP-Dx is described as cleared for primary clinical diagnosis in specified uses; Concentriq AP and Concentriq LS are for research use only. Proscia’s AI applications are also designated for research use, subject to applicable regulatory status. In October 2026, Agilent announced an agreement to acquire Proscia, subject to future performance milestones.